Jodi Buras
Primary Care · Covington, LANPI 1265409080
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 659 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 659 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- CSL Behring$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Grifols USA, LLC$896
- Takeda Pharmaceuticals U.S.A., Inc.$668
- plus $4K from 31 others
What the payments were for
- Consulting fees$650%
- Food & beverage$13,29498%
- Education$2062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 110 | $2,408 |
| CSL Behring | 74 | $2,219 |
| GSK | 143 | $2,105 |
| Regeneron Healthcare Solutions, Inc. | 73 | $1,574 |
| Grifols USA, LLC | 47 | $896 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $668 |
| Sanofi | 32 | $667 |
| Novartis | 25 | $498 |
| Amgen | 14 | $293 |
| Optinose US, Inc. | 15 | $284 |
| Genentech USA, Inc. | 9 | $192 |
| Pfizer | 9 | $178 |
| Blueprint Medicines Corporation | 6 | $156 |
| Mylan Specialty L.p. | 8 | $152 |
| AbbVie | 7 | $133 |
| Bio Products Laboratory USA, Inc. | 4 | $128 |
| ADMA Biomanufacturing LLC | 6 | $118 |
| Boehringer Ingelheim | 7 | $111 |
| LEO Pharma Inc. | 5 | $105 |
| Pharming Healthcare, Inc. | 4 | $92 |
| Biocryst US Sales Co., LLC | 3 | $66 |
| Verona Pharma, Inc. | 3 | $62 |
| Viatris Specialty LLC | 2 | $54 |
| Phadia US Inc. | 3 | $48 |
| Kaleo, Inc. | 3 | $46 |
| Eyevance Pharmaceuticals LLC | 2 | $40 |
| Galderma Laboratories, L.p. | 2 | $34 |
| Organon | 1 | $34 |
| Merck | 2 | $33 |
| Octapharma USA, Inc. | 1 | $29 |
| QOL Medical, LLC | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| GC Biopharma USA, Inc. | 1 | $21 |
| Kedrion Biopharma, Inc. | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| Alk-abello, Inc | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$205
- TRELEGY ELLIPTA$120
- AIRSUPRA$119
- Andembry$115
How this compares
$13,565 in reported general payments places this provider in the 95th percentile of 106 primary care providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $49,061 |
| XolairOmalizumab | 13 | $34,460 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $16,330 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,352 |
| Epinephrine | 39 | $8,285 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,621 |
| Azelastine Hcl | 99 | $3,054 |
| Levocetirizine Dihydrochloride | 222 | $2,684 |
| Fluticasone Propionate | 72 | $1,119 |
| Famotidine | 39 | $717 |
| Cefdinir | 39 | $692 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $675 |
| Montelukast Sodium | 105 | $656 |
| Pantoprazole Sodium | 40 | $528 |
| Azithromycin | 16 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $2,105 | $65,39193 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,408 | $14,97332 claims |
| Hikma Pharmaceuticals USAEpinephrine | $13 | $8,28539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 primary care providers in Louisiana.
Other primary care in Covington
- Alle NorrisCovington$6K
- Angela ParettiCovington$5K
- Wendy TaylorShreveport$15K
- Mia Schexnayder-DavisNew Orleans$10K
- Lourdes TorresMonroe$8K
- Danielle WebsterPrairieville$8K
- Ariel GrahamRayville$6K
- Eleisa FloydHouma$6K
- Emily FusilierBaton Rouge$5K
- Lindsay CloutierMorgan City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.